Elim Biopharmaceuticals specializes in advanced genomic technologies, particularly in the areas of DNA purification, sequencing, and synthesis. Their offerings include high-throughput DNA purification methods that ensure ultra-pure, endotoxin-free preparations, as well as rapid DNA sequencing services that provide high-quality reads with same-day turnaround options. The company also excels in whole plasmid sequencing, which delivers high-quality consensus sequences without the need for primers or PCR amplification, ensuring efficiency and reliability. Additionally, Elim's oligo synthesis and peptide synthesis services are designed for rapid delivery and high-quality outputs, catering to the needs of researchers in various fields.

A standout product from Elim is the RightOn Cancer Sequencing Kit, which provides a comprehensive solution for cancer profiling by targeting over 1,000 cancer-related genes. This kit utilizes advanced library preparation and target enrichment technologies, achieving exceptional coverage and specificity, with the ability to detect low-frequency variants in tumor samples. The RightOn kit is designed for efficiency, requiring minimal input DNA and offering significant cost savings compared to traditional sequencing methods. By integrating these technologies, Elim Biopharmaceuticals aims to enhance cancer research and diagnostics, facilitating a deeper understanding of the genetic underpinnings of cancer and enabling more targeted therapeutic approaches.

United States

Elim Biopharmaceuticals, Inc. is a leading life science service company for the biotech, pharmaceutical, and medical communities, offering a range of services from sequencing to synthesis, including drug quantification.

Elim Biopharmaceuticals

Company Details